Dengue Vaccine Dosage

Medically reviewed by Drugs.com. Last updated on Jul 25, 2023.

Usual Pediatric Dose for Infection Prophylaxis

6 to 16 years: 0.5 mL subcutaneously at months 0, 6, and 12 (3 doses total)

Comments:

• Not approved for use in individuals not previously infected by any dengue serotype or for whom information is unknown.
• Limitation of use: The safety and effectiveness of this vaccine have not been established in individuals living in dengue nonendemic areas who travel to dengue endemic areas.

Use: Prevention of dengue disease caused by dengue virus serotypes 1, 2, 3, and 4 in patients with laboratory-confirmed previous dengue infection and living in endemic areas

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

CONTRAINDICATIONS:

• History of a severe allergic reaction to a previous dose of this vaccine or to any of the components
• Individuals with severe immunodeficiency or immunosuppression due to disease or therapy

Safety and efficacy have not been established in patients younger than 6 years or older than 65 years old.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

• For subcutaneous use only
• Do not mix in the same syringe with other parenteral products

Storage requirements:

• After reconstitution, administer immediately or refrigerate at 2C to 8C (36F to 46F) and use within 30 minutes.
• Do not freeze.
• Protect from light.
• Do not use after expiration date

Reconstitution/preparation techniques:

• The manufacturer product information should be consulted.

General:

• Instruct vaccine recipients to report adverse reactions to their healthcare provider.
• Limitations of Use: This vaccine is not approved for use in individuals not previously infected by any dengue virus serotype or for whom this information is unknown. Those not previously infected are at increased risk for severe dengue disease when vaccinated and subsequently infected with dengue virus.

Monitoring:

• There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed during pregnancy. Exposed women or their healthcare professional can contact, Sanofi Pasteur Inc. at 1-800-822-2463 (1-800-VACCINE) to enroll in or obtain information about the registry.

Patient advice:

• Read the US FDA-approved patient labeling (Patient Information and Instructions for Use).

Frequently asked questions

• Why can't the dengue vaccine Dengvaxia be used in people who haven't already had dengue?

See also:

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer